Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs Paclitaxel in Advanced Gastric Cancer (KEYNOTE-063)
NCT03019588Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2017
- Primary completion
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
A Phase 3 trial of pembrolizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Merck & Co.. Started Feb 2017; status: terminated.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03019588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019588.